Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 120

1.

Development of adaptive immune effector therapies in solid tumors.

Comoli P, Chabannon C, Koehl U, Lanza F, Urbano-Ispizua A, Hudecek M, Ruggeri A, Secondino S, Bonini C, Pedrazzoli P.

Ann Oncol. 2019 Aug 21. pii: mdz285. doi: 10.1093/annonc/mdz285. [Epub ahead of print]

PMID:
31435646
2.

CAR-Expressing Natural Killer Cells for Cancer Retargeting.

Kloess S, Kretschmer A, Stahl L, Fricke S, Koehl U.

Transfus Med Hemother. 2019 Feb;46(1):4-13. doi: 10.1159/000495771. Epub 2019 Feb 5. Review.

3.

Development of Automated Separation, Expansion, and Quality Control Protocols for Clinical-Scale Manufacturing of Primary Human NK Cells and Alpharetroviral Chimeric Antigen Receptor Engineering.

Oberschmidt O, Morgan M, Huppert V, Kessler J, Gardlowski T, Matthies N, Aleksandrova K, Arseniev L, Schambach A, Koehl U, Kloess S.

Hum Gene Ther Methods. 2019 Jun;30(3):102-120. doi: 10.1089/hgtb.2019.039. Epub 2019 May 16.

4.

Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.

Kloess S, Oberschmidt O, Dahlke J, Vu XK, Neudoerfl C, Kloos A, Gardlowski T, Matthies N, Heuser M, Meyer J, Sauer M, Falk C, Koehl U, Schambach A, Morgan MA.

Hum Gene Ther. 2019 Apr;30(4):381-401. doi: 10.1089/hum.2018.247. Epub 2019 Mar 18.

PMID:
30734584
5.

Joint Modeling of Immune Reconstitution Post Haploidentical Stem Cell Transplantation in Pediatric Patients With Acute Leukemia Comparing CD34+-Selected to CD3/CD19-Depleted Grafts in a Retrospective Multicenter Study.

Salzmann-Manrique E, Bremm M, Huenecke S, Stech M, Orth A, Eyrich M, Schulz A, Esser R, Klingebiel T, Bader P, Herrmann E, Koehl U.

Front Immunol. 2018 Aug 14;9:1841. doi: 10.3389/fimmu.2018.01841. eCollection 2018.

6.

Dissecting Epstein-Barr Virus-Specific T-Cell Responses After Allogeneic EBV-Specific T-Cell Transfer for Central Nervous System Posttransplant Lymphoproliferative Disease.

Schultze-Florey RE, Tischer S, Kuhlmann L, Hundsdoerfer P, Koch A, Anagnostopoulos I, Ravens S, Goudeva L, Schultze-Florey C, Koenecke C, Blasczyk R, Koehl U, Heuft HG, Prinz I, Eiz-Vesper B, Maecker-Kolhoff B.

Front Immunol. 2018 Jun 27;9:1475. doi: 10.3389/fimmu.2018.01475. eCollection 2018.

7.

An Exponential Regression Model Reveals the Continuous Development of B Cell Subpopulations Used as Reference Values in Children.

Königs C, Schultze-Strasser S, Quaiser A, Bochennek K, Schwabe D, Klingebiel TE, Koehl U, Cappel C, Rolle U, Bader P, Bremm M, Huenecke S, Bakhtiar S.

Front Pediatr. 2018 May 4;6:121. doi: 10.3389/fped.2018.00121. eCollection 2018.

8.

Immune monitoring in allogeneic hematopoietic stem cell transplant recipients: a survey from the EBMT-CTIWP.

Greco R, Ciceri F, Noviello M, Bondanza A, Vago L, Oliveira G, Peccatori J, Cieri N, Ruggeri A, Koehl U, Fleischhauer K, Rocha V, Dazzi F, van der Werf SM, Eikema DJ, Terwel SR, Kuball J, Toubert A, Chabannon C, Bonini C; EBMT Cellular Therapy and Immunobiology Working Party (CTIWP).

Bone Marrow Transplant. 2018 Sep;53(9):1201-1205. doi: 10.1038/s41409-018-0167-8. Epub 2018 Apr 17. No abstract available.

PMID:
29666449
9.

Editorial: Tailoring NK Cell Receptor-Ligand Interactions: An Art in Evolution.

Koehl U, Toubert A, Pittari G.

Front Immunol. 2018 Feb 27;9:351. doi: 10.3389/fimmu.2018.00351. eCollection 2018. No abstract available.

10.

High-dose vitamin D in Addison's disease regulates T-cells and monocytes: A pilot trial.

Penna-Martinez M, Filmann N, Bogdanou D, Shoghi F, Huenecke S, Schubert R, Herrmann E, Koehl U, Husebye ES, Badenhoop K.

Nutrition. 2018 May;49:66-73. doi: 10.1016/j.nut.2017.10.021. Epub 2017 Dec 2.

PMID:
29522979
11.

Multidimensional Analysis Integrating Human T-Cell Signatures in Lymphatic Tissues with Sex of Humanized Mice for Prediction of Responses after Dendritic Cell Immunization.

Volk V, Reppas AI, Robert PA, Spineli LM, Sundarasetty BS, Theobald SJ, Schneider A, Gerasch L, Deves Roth C, Klöss S, Koehl U, von Kaisenberg C, Figueiredo C, Hatzikirou H, Meyer-Hermann M, Stripecke R.

Front Immunol. 2017 Dec 8;8:1709. doi: 10.3389/fimmu.2017.01709. eCollection 2017.

12.

Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.

Klöß S, Oberschmidt O, Morgan M, Dahlke J, Arseniev L, Huppert V, Granzin M, Gardlowski T, Matthies N, Soltenborn S, Schambach A, Koehl U.

Hum Gene Ther. 2017 Oct;28(10):897-913. doi: 10.1089/hum.2017.157. Epub 2017 Aug 15.

PMID:
28810809
13.

Influence of Irradiated Peripheral Blood Mononuclear Cells on Both Ex Vivo Proliferation of Human Natural Killer Cells and Change in Cellular Property.

Delso-Vallejo M, Kollet J, Koehl U, Huppert V.

Front Immunol. 2017 Jul 24;8:854. doi: 10.3389/fimmu.2017.00854. eCollection 2017.

14.

Natural Killer Cell-Based Cancer Immunotherapies: From Immune Evasion to Promising Targeted Cellular Therapies.

Hofer E, Koehl U.

Front Immunol. 2017 Jul 12;8:745. doi: 10.3389/fimmu.2017.00745. eCollection 2017.

15.

Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an "Off-the-Shelf Immunotherapy" for Improvement in Cancer Treatment.

Oberschmidt O, Kloess S, Koehl U.

Front Immunol. 2017 Jun 9;8:654. doi: 10.3389/fimmu.2017.00654. eCollection 2017. Review.

16.

Characterization of High-Avidity Cytomegalovirus-Specific T Cells with Differential Tetramer Binding Coappearing after Allogeneic Stem Cell Transplantation.

Ogonek J, Verma K, Schultze-Florey C, Varanasi P, Luther S, Schweier P, Kühnau W, Göhring G, Dammann E, Stadler M, Ganser A, Koehl U, Koenecke C, Weissinger EM, Hambach L.

J Immunol. 2017 Jul 15;199(2):792-805. doi: 10.4049/jimmunol.1601992. Epub 2017 Jun 19.

17.

Natural Killer Group 2D Ligand Depletion Reconstitutes Natural Killer Cell Immunosurveillance of Head and Neck Squamous Cell Carcinoma.

Weil S, Memmer S, Lechner A, Huppert V, Giannattasio A, Becker T, Müller-Runte A, Lampe K, Beutner D, Quaas A, Schubert R, Herrmann E, Steinle A, Koehl U, Walter L, von Bergwelt-Baildon MS, Koch J.

Front Immunol. 2017 Apr 10;8:387. doi: 10.3389/fimmu.2017.00387. eCollection 2017.

18.

Possible Impact of Cytomegalovirus-Specific CD8+ T Cells on Immune Reconstitution and Conversion to Complete Donor Chimerism after Allogeneic Stem Cell Transplantation.

Ogonek J, Varanasi P, Luther S, Schweier P, Kühnau W, Göhring G, Dammann E, Stadler M, Ganser A, Borchers S, Koehl U, Weissinger EM, Hambach L.

Biol Blood Marrow Transplant. 2017 Jul;23(7):1046-1053. doi: 10.1016/j.bbmt.2017.03.027. Epub 2017 Mar 23.

19.

Percentiles of Lymphocyte Subsets in Preterm Infants According to Gestational Age Compared to Children and Adolescents.

Huenecke S, Fryns E, Wittekindt B, Buxmann H, Königs C, Quaiser A, Fischer D, Bremm M, Klingebiel T, Koehl U, Schloesser R, Bochennek K.

Scand J Immunol. 2016 Nov;84(5):291-298. doi: 10.1111/sji.12474.

20.

T-lymphocyte and glycemic status after vitamin D treatment in type 1 diabetes: A randomized controlled trial with sequential crossover.

Bogdanou D, Penna-Martinez M, Filmann N, Chung TL, Moran-Auth Y, Wehrle J, Cappel C, Huenecke S, Herrmann E, Koehl U, Badenhoop K.

Diabetes Metab Res Rev. 2017 Mar;33(3). doi: 10.1002/dmrr.2865. Epub 2016 Dec 6.

PMID:
27764529
21.

Automated Enrichment, Transduction, and Expansion of Clinical-Scale CD62L+ T Cells for Manufacturing of Gene Therapy Medicinal Products.

Priesner C, Aleksandrova K, Esser R, Mockel-Tenbrinck N, Leise J, Drechsel K, Marburger M, Quaiser A, Goudeva L, Arseniev L, Kaiser AD, Glienke W, Koehl U.

Hum Gene Ther. 2016 Oct;27(10):860-869. doi: 10.1089/hum.2016.091.

22.

Specific phenotype and function of CD56-expressing innate immune cell subsets in human thymus.

Gerstner S, Köhler W, Heidkamp G, Purbojo A, Uchida S, Ekici AB, Heger L, Luetke-Eversloh M, Schubert R, Bader P, Klingebiel T, Koehl U, Mackensen A, Romagnani C, Cesnjevar R, Dudziak D, Ullrich E.

J Leukoc Biol. 2016 Dec;100(6):1297-1310. Epub 2016 Jun 28.

PMID:
27354408
23.

Optimization of individualized graft composition: CD3/CD19 depletion combined with CD34 selection for haploidentical transplantation.

Huenecke S, Bremm M, Cappel C, Esser R, Quaiser A, Bonig H, Jarisch A, Soerensen J, Klingebiel T, Bader P, Koehl U.

Transfusion. 2016 Sep;56(9):2336-45. doi: 10.1111/trf.13694. Epub 2016 Jun 27.

PMID:
27346253
24.

Advances in clinical NK cell studies: Donor selection, manufacturing and quality control.

Koehl U, Kalberer C, Spanholtz J, Lee DA, Miller JS, Cooley S, Lowdell M, Uharek L, Klingemann H, Curti A, Leung W, Alici E.

Oncoimmunology. 2015 Nov 11;5(4):e1115178. eCollection 2016 Apr.

25.

Immune cell subsets at birth may help to predict risk of late-onset sepsis and necrotizing enterocolitis in preterm infants.

Bochennek K, Fryns E, Wittekindt B, Buxmann H, Quaiser A, Fischer D, Klingebiel T, Koehl U, Schloesser R, Huenecke S.

Early Hum Dev. 2016 Feb;93:9-16. doi: 10.1016/j.earlhumdev.2015.10.018. Epub 2015 Dec 17.

PMID:
26704574
26.

Generation and flow cytometric quality control of clinical-scale TCRαβ/CD19-depleted grafts.

Bremm M, Cappel C, Erben S, Jarisch A, Schumm M, Arendt A, Bonig H, Klingebiel T, Koehl U, Bader P, Huenecke S.

Cytometry B Clin Cytom. 2017 Mar;92(2):126-135. doi: 10.1002/cyto.b.21328. Epub 2015 Dec 14.

27.

Efficient generation of gene-modified human natural killer cells via alpharetroviral vectors.

Suerth JD, Morgan MA, Kloess S, Heckl D, Neudörfl C, Falk CS, Koehl U, Schambach A.

J Mol Med (Berl). 2016 Jan;94(1):83-93. doi: 10.1007/s00109-015-1327-6. Epub 2015 Aug 25.

PMID:
26300042
28.

Generation of lentivirus-induced dendritic cells under GMP-compliant conditions for adaptive immune reconstitution against cytomegalovirus after stem cell transplantation.

Sundarasetty BS, Kloess S, Oberschmidt O, Naundorf S, Kuehlcke K, Daenthanasanmak A, Gerasch L, Figueiredo C, Blasczyk R, Ruggiero E, Fronza R, Schmidt M, von Kalle C, Rothe M, Ganser A, Koehl U, Stripecke R.

J Transl Med. 2015 Jul 22;13:240. doi: 10.1186/s12967-015-0599-5.

29.

Consensus of German transplant centers on hematopoietic stem cell transplantation in Fanconi anemia.

Chao MM, Ebell W, Bader P, Beier R, Burkhardt B, Feuchtinger T, Handgretinger R, Hanenberg H, Koehl U, Kratz C, Kremens B, Lang P, Meisel R, Mueller I, Roessig C, Sauer M, Schlegel PG, Schulz A, Strahm B, Thol F, Sykora KW.

Klin Padiatr. 2015 May;227(3):157-65. doi: 10.1055/s-0035-1548841. Epub 2015 May 18.

30.

Successful Combination of Sequential Gene Therapy and Rescue Allo-HSCT in Two Children with X-CGD - Importance of Timing.

Siler U, Paruzynski A, Holtgreve-Grez H, Kuzmenko E, Koehl U, Renner ED, Alhan C, de Loosdrecht AA, Schwäble J, Pfluger T, Tchinda J, Schmugge M, Jauch A, Naundorf S, Kühlcke K, Notheis G, Güngor T, Kalle CV, Schmidt M, Grez M, Seger R, Reichenbach J.

Curr Gene Ther. 2015;15(4):416-27.

PMID:
25981636
31.

Lentivirus-induced 'Smart' dendritic cells: Pharmacodynamics and GMP-compliant production for immunotherapy against TRP2-positive melanoma.

Sundarasetty BS, Chan L, Darling D, Giunti G, Farzaneh F, Schenck F, Naundorf S, Kuehlcke K, Ruggiero E, Schmidt M, von Kalle C, Rothe M, Hoon DS, Gerasch L, Figueiredo C, Koehl U, Blasczyk R, Gutzmer R, Stripecke R.

Gene Ther. 2015 Sep;22(9):707-20. doi: 10.1038/gt.2015.43. Epub 2015 May 28.

32.

Cytotoxicity and infiltration of human NK cells in in vivo-like tumor spheroids.

Giannattasio A, Weil S, Kloess S, Ansari N, Stelzer EH, Cerwenka A, Steinle A, Koehl U, Koch J.

BMC Cancer. 2015 May 3;15:351. doi: 10.1186/s12885-015-1321-y.

33.

Advantages and applications of CAR-expressing natural killer cells.

Glienke W, Esser R, Priesner C, Suerth JD, Schambach A, Wels WS, Grez M, Kloess S, Arseniev L, Koehl U.

Front Pharmacol. 2015 Feb 12;6:21. doi: 10.3389/fphar.2015.00021. eCollection 2015. Review.

34.

5-lipoxygenase is a direct target of miR-19a-3p and miR-125b-5p.

Busch S, Auth E, Scholl F, Huenecke S, Koehl U, Suess B, Steinhilber D.

J Immunol. 2015 Feb 15;194(4):1646-53. doi: 10.4049/jimmunol.1402163. Epub 2015 Jan 14.

35.

Rapid generation of clinical-grade antiviral T cells: selection of suitable T-cell donors and GMP-compliant manufacturing of antiviral T cells.

Tischer S, Priesner C, Heuft HG, Goudeva L, Mende W, Barthold M, Kloeß S, Arseniev L, Aleksandrova K, Maecker-Kolhoff B, Blasczyk R, Koehl U, Eiz-Vesper B.

J Transl Med. 2014 Dec 16;12:336. doi: 10.1186/s12967-014-0336-5.

36.

Interleukin-2-stimulated natural killer cells are less susceptible to mycophenolate mofetil than non-activated NK cells: possible consequences for immunotherapy.

Brehm C, Huenecke S, Esser R, Kloess S, Quaiser A, Betz S, Zimmermann O, Soerensen J, Passweg JR, Klingebiel T, Schwabe D, Bader P, Koehl U.

Cancer Immunol Immunother. 2014 Aug;63(8):821-33. doi: 10.1007/s00262-014-1556-5. Epub 2014 May 8.

PMID:
24806448
37.

Multimer monitoring of CMV-specific T cells in research and in clinical applications.

Borchers S, Ogonek J, Varanasi PR, Tischer S, Bremm M, Eiz-Vesper B, Koehl U, Weissinger EM.

Diagn Microbiol Infect Dis. 2014 Mar;78(3):201-12. doi: 10.1016/j.diagmicrobio.2013.11.007. Epub 2013 Nov 15. Review.

PMID:
24331953
38.

Natural ligands and antibody-based fusion proteins: harnessing the immune system against cancer.

Vyas M, Koehl U, Hallek M, von Strandmann EP.

Trends Mol Med. 2014 Feb;20(2):72-82. doi: 10.1016/j.molmed.2013.10.006. Epub 2013 Nov 19. Review.

PMID:
24268686
39.

Myeloid and plasmacytoid dendritic cells: reference ranges in the peripheral blood of healthy children.

Ciocarlie O, Heinze A, Elze MC, Kloess S, Klingebiel T, Serban M, Koehl U.

Klin Padiatr. 2013 Nov;225(6):354-6. doi: 10.1055/s-0033-1355428. Epub 2013 Oct 24. Review.

PMID:
24158895
40.

Regulation of advanced therapy medicinal products in Europe and the role of academia.

Pearce KF, Hildebrandt M, Greinix H, Scheding S, Koehl U, Worel N, Apperley J, Edinger M, Hauser A, Mischak-Weissinger E, Dickinson AM, Lowdell MW.

Cytotherapy. 2014 Mar;16(3):289-97. doi: 10.1016/j.jcyt.2013.08.003. Epub 2013 Oct 8. Review.

PMID:
24113428
41.

Treatment of patients with advanced cancer with the natural killer cell line NK-92.

Tonn T, Schwabe D, Klingemann HG, Becker S, Esser R, Koehl U, Suttorp M, Seifried E, Ottmann OG, Bug G.

Cytotherapy. 2013 Dec;15(12):1563-70. doi: 10.1016/j.jcyt.2013.06.017. Epub 2013 Oct 1.

PMID:
24094496
42.

Clinical grade purification and expansion of NK cell products for an optimized manufacturing protocol.

Koehl U, Brehm C, Huenecke S, Zimmermann SY, Kloess S, Bremm M, Ullrich E, Soerensen J, Quaiser A, Erben S, Wunram C, Gardlowski T, Auth E, Tonn T, Seidl C, Meyer-Monard S, Stern M, Passweg J, Klingebiel T, Bader P, Schwabe D, Esser R.

Front Oncol. 2013 May 17;3:118. doi: 10.3389/fonc.2013.00118. eCollection 2013.

43.

No effect of antifungal compounds on functional properties of human antifungal T-helper type 1 cells.

Tramsen L, Schmidt S, Koehl U, Huenecke S, Latgé JP, Roeger F, Schubert R, Klingebiel T, Lehrnbecher T.

Transpl Infect Dis. 2013 Aug;15(4):430-4. doi: 10.1111/tid.12089. Epub 2013 May 6.

PMID:
23647945
44.

Natural killer cells and antifungal host response.

Schmidt S, Zimmermann SY, Tramsen L, Koehl U, Lehrnbecher T.

Clin Vaccine Immunol. 2013 Apr;20(4):452-8. doi: 10.1128/CVI.00606-12. Epub 2013 Jan 30. Review.

45.

Age-matched dendritic cell subpopulations reference values in childhood.

Heinze A, Elze MC, Kloess S, Ciocarlie O, Königs C, Betz S, Bremm M, Esser R, Klingebiel T, Serban M, Hutton JL, Koehl U.

Scand J Immunol. 2013 Mar;77(3):213-20. doi: 10.1111/sji.12024.

46.

Sequential anti-cytomegalovirus response monitoring may allow prediction of cytomegalovirus reactivation after allogeneic stem cell transplantation.

Borchers S, Bremm M, Lehrnbecher T, Dammann E, Pabst B, Wölk B, Esser R, Yildiz M, Eder M, Stadler M, Bader P, Martin H, Jarisch A, Schneider G, Klingebiel T, Ganser A, Weissinger EM, Koehl U.

PLoS One. 2012;7(12):e50248. doi: 10.1371/journal.pone.0050248. Epub 2012 Dec 13. Erratum in: PLoS One. 2013;8(4). doi: 10.1371/annotation/43e9b84c-fbe3-4b39-88c8-1cde34b0afea.

47.

Immunosenescence-associated microRNAs in age and heart failure.

Seeger T, Haffez F, Fischer A, Koehl U, Leistner DM, Seeger FH, Boon RA, Zeiher AM, Dimmeler S.

Eur J Heart Fail. 2013 Apr;15(4):385-93. doi: 10.1093/eurjhf/hfs184. Epub 2012 Dec 20.

48.

Rhizopus oryzae hyphae are damaged by human natural killer (NK) cells, but suppress NK cell mediated immunity.

Schmidt S, Tramsen L, Perkhofer S, Lass-Flörl C, Hanisch M, Röger F, Klingebiel T, Koehl U, Lehrnbecher T.

Immunobiology. 2013 Jul;218(7):939-44. doi: 10.1016/j.imbio.2012.10.013. Epub 2012 Nov 2.

PMID:
23201314
49.

Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers.

Stern M, Passweg JR, Meyer-Monard S, Esser R, Tonn T, Soerensen J, Paulussen M, Gratwohl A, Klingebiel T, Bader P, Tichelli A, Schwabe D, Koehl U.

Bone Marrow Transplant. 2013 Mar;48(3):433-8. doi: 10.1038/bmt.2012.162. Epub 2012 Sep 3.

PMID:
22941380
50.

Impact of minimal residual disease detection prior to autologous stem cell transplantation for post-transplant outcome in high risk neuroblastoma.

Bochennek K, Esser R, Lehrnbecher T, Glienke W, Wehner S, Erben S, Soerensen J, Schwabe D, Bader P, Klingebiel T, Koehl U.

Klin Padiatr. 2012 Apr;224(3):139-42. doi: 10.1055/s-0031-1301334. Epub 2012 Feb 29.

PMID:
22377741

Supplemental Content

Support Center